

1 **Title: Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in**
2 **infliximab- and vedolizumab-treated patients**

3 **Authors:** Simeng Lin, MBChB^{1,2†}, Nicholas A Kennedy, PhD^{1,2†}, Aamir Saifuddin, BM.BCh^{3,4†} Diana
4 Muñoz Sandoval PhD^{5†}, Catherine J Reynolds PhD⁵, Rocio Castro Seoane, PhD⁶, Sherine H Kottoor,
5 PhD⁴, Franziska P Pieper MSc⁵, Kai-Min Lin PhD⁵, David K. Butler MSc⁵, Neil Chanchlani, MBChB^{1,2},
6 Rachel Nice, MSc^{2,7}, Desmond Chee, MBBS^{1,2}, Claire Bewshea, MSc², Malik Janjua, MBBS^{1,2}, Timothy J
7 McDonald, PhD⁷, Shaji Sebastian, MD^{8,9}, James L Alexander, PhD,^{4,10} Laura Constable, MRes⁴, James C
8 Lee PhD^{11,12,13}, Charles D Murray PhD¹¹, Ailsa L Hart PhD³, Peter M Irving, MD^{14,15}, Gareth-Rhys
9 Jones,^{16,17} Klaartje B Kok, PhD^{18,19}, Christopher A Lamb, PhD^{20,21}, Charlie W Lees, PhD^{16,22}, Daniel M
10 Altmann PhD⁶, Rosemary J Boyton PhD^{5,23†}, James R Goodhand, MBBS^{1,2†}, Nick Powell, PhD^{4,10†}, Tariq
11 Ahmad, DPhil^{1,2*†}, Contributors of the CLARITY IBD study.

12 † Denotes equal contribution

13 * Corresponding author

14
15 Affiliations:

16 ¹Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK

17 ² Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter,
18 UK

19 ³Department of Gastroenterology, St Marks Hospital and Academic Institute, London, UK

20 ⁴Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK

21 ⁵Department of Infectious Disease, Imperial College London, London, UK

22 ⁶Department of Immunology and Inflammation, Imperial College London, London, United Kingdom

23 ⁷Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter NHS
24 Foundation Trust, Exeter, UK

- 25 ⁸IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK
- 26 ⁹Hull York Medical School, University of Hull, Hull, UK
- 27 ¹⁰Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK
- 28 ¹¹Department of Gastroenterology, Royal Free London NHS Foundation Trust, London, UK
- 29 ¹²Genetic Mechanisms of Disease Laboratory, The Francis Crick Institute, London, UK
- 30 ¹³Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical
31 Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK
- 32 ¹⁴Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK
- 33 ¹⁵School of Immunology & Microbial Sciences, King's College London, London, UK
- 34 ¹⁶Department of Gastroenterology, Western General Hospital, NHS Lothian, Edinburgh, UK
- 35 ¹⁷Centre for Inflammation Research, The Queen's Medical Research Institute, The University of
36 Edinburgh, Edinburgh, UK
- 37 ¹⁸Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UK
- 38 ¹⁹Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen
39 Mary University of London, London, UK
- 40 ²⁰Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust,
41 Newcastle upon Tyne, UK
- 42 ²¹Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University,
43 Newcastle upon Tyne, UK
- 44 ²²Institute of Genetic and Molecular Medicine, University of Edinburgh, Edinburgh, UK
- 45 ²³Lung Division, Royal Brompton Hospital and Harefield Hospitals, London, UK
- 46

47 **Address for correspondence:** Prof Tariq Ahmad, Exeter Inflammatory Bowel Disease and
48 Pharmacogenetics Research Group, RILD building, Barrack Road, Exeter. EX2 5DW,
49 UK, tariq.ahmad1@nhs.net

50

51 **Key words:** SARS-CoV-2, SARS-CoV-2 antibody decay, immune-mediated inflammatory diseases,
52 inflammatory bowel disease, anti-TNF therapy, infliximab, vedolizumab, immunosuppressant,
53 vaccine, ChAdOx1 nCoV-19, BNT162b2, CLARITY, T-Lymphocytes

54 **Word count (including methods): 4189**

55 **Abstract**

56 We report SARS-CoV-2 vaccine-induced immunity and risk of breakthrough infections in
57 patients with inflammatory bowel disease treated with infliximab, a commonly used anti-TNF
58 drug and those treated with vedolizumab, a gut-specific antibody targeting integrin $\alpha 4\beta 7$ that does
59 not impact systemic immunity. In infliximab-treated patients, the magnitude of anti-SARS-CoV2
60 antibodies was reduced 4-6-fold. One fifth of both infliximab- and vedolizumab-treated patients did
61 not mount a T cell response. Antibody half-life was shorter in infliximab-treated patients.
62 Breakthrough SARS-CoV-2 infections occurred more frequently in infliximab-treated patients and the
63 risk was predicted by the level of antibody response after second vaccine dose. Overall, recipients of
64 two doses of the BNT162b2 vaccine had higher anti-SARS-CoV-2 antibody concentrations,
65 higher seroconversion rates, shorter antibody half-life and less breakthrough infections compared
66 to ChAdOx1 nCoV-19 vaccine recipients. Irrespective of biologic treatment, higher, more sustained
67 antibody levels were observed in patients with a history of SARS-CoV-2 infection prior to
68 vaccination. Patients treated with anti-TNF therapy should be offered third vaccine doses.
69

70 **Introduction**

71 Vaccination programmes have reduced SARS-CoV-2 transmission, hospitalisation and deaths¹.
72 Patients treated with immunosuppressive drugs were excluded from the original trials for COVID-19
73 vaccines^{2,3}. Consequently, data relating to the magnitude and durability of immune responses and
74 subsequent vaccine effectiveness in this population are limited⁴.

75

76 Drugs targeting tumor necrosis factor (TNF), such as infliximab, are the most frequently prescribed
77 biological therapies used in the treatment of immune-mediated inflammatory disorders (IMiDs).

78 Observational studies indicate that most patients with inflammatory bowel disease (IBD), an
79 archetypal IMiD, mount serological responses following SARS-CoV-2 vaccines, although most were
80 underpowered to discern the impact of specific drugs, including immunomodulators (azathioprine,
81 mercaptopurine, and methotrexate) and/or biologic therapies⁵⁻⁸. We reported that antibody
82 responses following SARS-CoV-2 infection^{9,10} or a single-dose of either the BNT162b2 or ChAdOx1
83 nCoV-19 SARS-CoV-2 vaccines were impaired in anti-TNF treated patients when compared to
84 vedolizumab treated patients¹¹. Vedolizumab, is a gut-selective anti-integrin $\alpha4\beta7$ monoclonal
85 antibody that, unlike anti-TNF drugs is not associated with increased susceptibility to systemic
86 infection or attenuated serological responses to vaccination¹².

87

88 Here we compare immune responses between infliximab- and vedolizumab-treated patients with
89 IBD who received two doses of the BNT162b2 or ChAdOx1 nCoV-19 vaccines. We hypothesised that,
90 irrespective of the type of vaccine, antibody and T cell responses would be attenuated and less
91 durable with an associated increased risk of breakthrough SARS-CoV-2 infections in patients treated
92 with infliximab.

93

94 **Results**

95 ***Patient characteristics***

96 Between September 22nd 2020 and December 23rd 2020, 7,226 patients were recruited to the
97 CLARITY study from 92 UK hospitals¹⁰. In this analysis we included 2,264 infliximab- and 1,024
98 vedolizumab-treated participants without a history of prior SARS-CoV-2 infection, who had received
99 uninterrupted biologic therapy since recruitment and had an antibody test between 14 and 70 days
100 after a second-dose of the either the BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines.
101 Participant characteristics are shown in Table 1.

102

103 Additional analyses are presented for a subset of 211 infliximab- and 71 vedolizumab-treated
104 patients included in our T cell experiments (Supplementary Table 2), and a further 525 infliximab-
105 and 224 vedolizumab-treated participants who had a history of SARS-CoV-2 infection before
106 vaccination (Supplementary Table 3).

107

108 ***Anti-SARS-CoV-2 (S) antibody level following second COVID-19 vaccine***

109 Overall, the geometric mean [geometric SD] of anti-S RBD antibody concentration was higher in
110 recipients of two doses of the BNT162b2 than ChAdOx1 nCoV-19 vaccines (1080.2 U/mL [7.6] vs
111 289.9 U/mL[5.2], $p < 0.0001$). Anti-S RBD antibody concentrations were lower in patients treated
112 with infliximab than in those treated with vedolizumab, following a second dose of BNT162b2 (565.1
113 U/mL [6.2] vs 4527.6 U/mL [5.4], $p < 0.0001$) and ChAdOx1 nCoV-19 (184.5 U/mL [5.0] vs 786.2 U/mL
114 [3.5], $p < 0.0001$) vaccines (Fig. 1).

115

116 Crude sensitivity analyses, excluding patients treated with a concomitant immunomodulator,
117 confirmed lower anti-S RBD antibody concentrations in patients treated with infliximab alone versus

118 vedolizumab alone (BNT162b2 816.5 U/mL [4.9] vs 4616.3U/mL [6.0], $p < 0.0001$, ChAdOx1 nCoV-19
119 181.4 U/mL [4.4] vs 774.9 U/mL [3.6], $p < 0.0001$).

120 After propensity matching for immunomodulator use and the other factors associated with choice of
121 biologic, we confirmed lower anti-S RBD antibody concentrations in infliximab- compared to
122 vedolizumab-treated patients (BNT162b2 587.9 U/mL [6.1] vs 4657.5U/mL [4.7], $p < 0.0001$,
123 ChAdOx1 nCoV-19 191.1 U/mL [4.7] vs 778.6 U/mL [3.7], $p < 0.0001$) (Supplementary Table 4).

124

125 Multivariable linear regression analyses in patients without prior SARS-CoV-2 infection confirmed
126 that antibody concentrations were reduced four and six-fold in infliximab- compared with
127 vedolizumab- treated participants who received the BNT162b2 (fold change [FC] 0.15 [95% CI 0.12,
128 0.19], $p < 0.0001$) and ChAdOx1 nCoV-19 ([FC] 0.24 [95% CI 0.20, 0.28], $p < 0.0001$) vaccines (Fig. 2a
129 and Fig. 2b respectively). Age ≥ 60 years and Crohn's disease were also independently associated
130 with lower anti-S RBD antibody concentrations in vaccinated participants. Thiopurine or
131 methotrexate use was independently associated with lower anti-S RBD antibody concentrations in
132 participants who received the BNT162b2, but not the ChAdOx1 nCoV-19 vaccine. Current smoking,
133 non-white ethnicity and steroid use were associated with lower anti-S RBD antibody concentrations
134 in participants who received the ChAdOx1 nCoV-19 but not the BNT162b2 vaccine. To assess the
135 effect of vaccine type on antibody responses, we combined our response data in a model that
136 included vaccine type in addition to the significant factors above. Vaccination with the BNT162b2
137 vaccine compared to the ChAdOx1 nCoV-19 was independently associated with a 3.7 fold [95% CI
138 3.28 – 4.12] higher anti-S RBD antibody concentration ($p < 0.0001$) (Fig. 2c).

139

140 Seroconversion rates after the first vaccine dose were lower in infliximab- compared to
141 vedolizumab-treated participants (Fig. 1). However, administration of a second vaccine dose resulted
142 in a >100 -fold and >25 fold increase in antibody concentrations in recipients of the BNT162b2 and
143 ChAdOx1 nCoV-19 vaccines, respectively (Fig. 1). Overall, more infliximab- than vedolizumab-treated

144 patients failed to seroconvert after their second vaccine dose (5.9% vs 1.3%, $p < 0.0001$).

145 Seroconversion rates stratified by biologic therapy and vaccine type are reported in Supplementary

146 Fig 1.

147

148 ***Anti-spike T cell responses following two doses of BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2***

149 ***vaccines***

150 There were no significant differences in the magnitude of anti-spike T cell responses observed in

151 infliximab- compared with vedolizumab-treated patients after one or two doses of either vaccine

152 (Fig. 3a). The proportion of patients failing to mount detectable T cell responses were similar in both

153 groups (infliximab 19.6% vs. vedolizumab 19.2%). For recipients of one and two doses of BNT162b2

154 vaccine there was a modest positive correlation between T cell responses and antibody

155 concentration. This association was not observed in recipients following either dose of the ChAdOx1

156 nCoV-19 vaccine (Fig. 3b). When T cell responses were ranked by magnitude of antibody responses,

157 most patients who did not mount an antibody response after the first vaccine dose (indicated by the

158 dark grey bar) had a detectable T cell response (Fig. 4). In addition to the uncoupling of the T cell and

159 antibody responses demonstrated, this analysis emphasised that about one fifth of participants

160 made no T cell responses irrespective of vaccine used (indicated by the light grey bars). Moreover,

161 a minority of individuals (3/67) 4.5% for BNT162b2 and (1/56) 1.8% for ChAdOx1 nCoV-19 vaccines

162 carry neither detectable antibody nor T cell responses after two doses of vaccine (Fig. 3b, Fig. 4).

163

164 ***Durability of antibody responses following two doses of BNT162b2 and ChAdOx1 nCoV-19 SARS-***

165 ***CoV-2 vaccines***

166 The estimated half-life of anti-S RBD antibodies was shorter in participants receiving the BNT162b2

167 compared to the ChAdOx1 nCoV-19 vaccines (4.6 weeks [95% CI 4.44 – 4.74] vs 5.9 weeks [95% CI

168 5.88 – 6.29], p value < 0.0001). When stratified by biologic, half-life estimates were shorter in

169 infliximab- than vedolizumab-treated patients following two-doses of BNT162b2 (4.0 weeks [95% CI
170 3.8 – 4.1] vs 7.2 weeks [95% CI 6.8 – 7.6]) and ChAdOx1 nCoV-19 (5.3 weeks [95% CI 5.1 – 5.5] vs 9.3
171 weeks [95% CI 8.5 – 10.2], p value < 0.0001) (Supplementary Fig. 2 and Supplementary Table 5).
172 Overall, following two doses of either vaccine, anti-S RBD antibodies showed minimal decay to last
173 follow-up in patients treated with vedolizumab (Fig. 5) and were similar to those observed in
174 participants in the Virus Watch community cohort (Supplementary Fig. 4). However, in infliximab-
175 treated participants the geometric mean concentrations dropped to the seroconversion threshold by
176 about 25 weeks after the second dose irrespective of vaccine administered (Fig. 5). Infliximab
177 compared to vedolizumab treatment, current smoking and white ethnicity were associated with a
178 faster fall in anti-S RBD antibody concentration below the seroconversion threshold.
179 (Supplementary Fig. 5, 6).

180

181 ***Breakthrough SARS-CoV-2 infections following two doses of vaccine***

182

183 267/5123 participants without PCR-positive or serological evidence of prior SARS-CoV-2 infection
184 had a first positive SARS-CoV-2 PCR test two or more weeks after the second vaccine dose. Overall,
185 89.2% patients were symptomatic: the most commonly reported symptoms were fatigue (73.7%),
186 anosmia/ageusia (71.4%), fever (57.1%), cough (54.9%), myalgia (45.9%), hoarse voice (30.8%),
187 confusion (27.8%) and chest pains (23.3%). 1.2% (3/251) of participants with PCR confirmed
188 infection were hospitalised because of COVID-19.

189

190 Breakthrough SARS-CoV-2 infections were more frequent (5.8% (201/3441) vs 3.9% (66/1682), p =
191 0.0039) and the time to breakthrough shorter in patients treated with infliximab than vedolizumab
192 (p = 0.0027) (Fig. 6b). In contrast biologic class did not impact on time to PCR confirmed infection
193 prior to vaccination (p = 0.63) (Fig. 6a). In a model that included biologic and vaccine type, shorter
194 time to breakthrough infection was associated with infliximab (Hazard Ratio (HR) 1.52 [95% CI 1.15 –

195 2.01], $p = 0.003$) and having received the ChAdOx1 nCoV-19 (HR 1.49 [95% CI 1.15 – 1.92], $p =$
196 0.0023) vaccine. Geometric mean [geometric SD] anti-S RBD antibody concentrations measured 2 to
197 10 weeks after a second vaccine dose were significantly lower in participants who subsequently had
198 a PCR confirmed breakthrough SARS-CoV-2 infection: for every 10-fold rise in anti-S RBD antibody
199 level we observed a 0.8-fold reduction in odds of breakthrough infection ([95% CI 0.70 – 0.99], $p =$
200 0.03).

201

202 ***Antibody responses in patients with prior SARS-CoV-2 infection***

203 Amongst patients with a history of SARS-CoV-2 infection before vaccination, geometric mean [SD]
204 anti-S RBD antibody concentrations were lower in infliximab- compared with vedolizumab-treated
205 patients after a second dose of BNT162b2 (1330.0 U/mL [5.3] vs 7169.5 U/mL [4.6], $p < 0.0001$) and
206 ChAdOx1 nCoV-19 (401.2 U/mL [5.5] vs 2077.3 [4.6] $p < 0.0001$) vaccines. In all patients, antibody
207 concentrations following vaccination were higher in patients without a history of SARS-CoV-2
208 infection (Fig. 1). Irrespective of vaccine or biologic type, minimal decay of anti-S RBD antibodies
209 were observed up to a follow-up of 21 weeks.

210 **Discussion**

211 We have shown that in infliximab-treated patients, anti-SARS-CoV-2 spike antibody responses are
212 attenuated following two doses of the BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. One
213 fifth of both infliximab- and vedolizumab-treated patients did not mount a T cell response and a
214 small subset of patients had neither antibody nor T cell responses. Antibody half-lives were shorter
215 in infliximab treated patients. Breakthrough SARS-CoV-2 infections were more common and
216 occurred earlier in infliximab-treated patients who received the ChAdOx1 nCoV-19 vaccine. The risk
217 of breakthrough infection was predicted by lower antibody levels after the second dose of vaccine.
218 Irrespective of biologic treatment, higher and more sustained antibody levels, were observed in
219 patients with a history of SARS-CoV-2 infection.

220

221 Sustained antibody responses observed in vaccinated patients with a history of prior SARS-CoV-2
222 infection indicates that third antigen exposure enhances the serological response. This supports the
223 rationale for prioritising a third dose of vaccine to clinically vulnerable patient populations¹³⁻¹⁶, who
224 otherwise may face further periods of social distancing or hospitalisation following infection. Whilst
225 drawing direct comparisons between IBD patients and patients treated with more potent
226 chemotherapies is limited by the degree to which patients are immunosuppressed, data from solid
227 organ transplant recipients shows that a third dose of vaccine also leads to sustained immune
228 responses¹⁷.

229

230 Irrespective of biologic or immunosuppressant use, and in keeping with the original trials^{2,18}, the
231 highest antibody responses were seen in recipients of the BNT162b2 vaccine. Like in the general
232 population these responses waned more quickly than in the recipients of the ChAdOx1 nCoV-19
233 vaccine¹⁹. Unlike the general population²⁰, but similar to renal transplant recipients⁴, we did not
234 observe differences in T cell ELISpot responses between recipients of the BNT162b2 and ChAdOx1
235 nCoV-19 vaccines. The differences observed in breakthrough infection by vaccine type reported here
236 are consistent with the differences in efficacy reported in the respective clinical trials^{2,3,21}. The
237 higher peak antibody levels and the lower rate of SARS-CoV-2 breakthrough infections suggest that
238 the BNT162b2 rather than the ChAdOx1 nCoV-19 vaccine should be used for primary vaccination in
239 infliximab-treated patients and although untested supports the use of BNT162b2 for third doses in
240 all patients treated with an anti-TNF regardless of the primary vaccine type.

241

242 All patients treated with anti-TNF therapy should receive a third primary dose of SARS-CoV-2
243 vaccine and our data support recent recommendations that this should occur about 4-8 weeks after
244 the second dose^{13,14,16} during periods of high transmission in the population. Our data demonstrate

245 that patients treated with vedolizumab and infliximab-treated patients with prior SARS-CoV-2
246 infection have sustained antibody levels beyond 6 months.

247

248 When starting a biologic, it would be reasonable to consider differences in SARS-CoV-2 vaccine
249 response as one of the factors when determining which drug to use. For patients who need to start
250 anti-TNF therapy, the benefits of combination immunomodulator therapy should be weighed against
251 the risk of attenuated vaccine response and whenever feasible, patients should first receive a SARS-
252 CoV-2 vaccine dose. Further research to determine whether timing third vaccine doses towards the
253 end of anti-TNF treatment cycles when drug levels are lowest leads to greater immunogenicity⁹ is
254 needed. Other strategies including the temporary discontinuation of immunomodulators²², the use
255 of heterologous vaccines²³ and adjuvants including the influenza vaccines (ComFluCOV)²⁴ need to be
256 studied in immunosuppressed patient groups.

257

258 The biology underpinning loss of durable antibody responses and uncoupling of the B cell and T cell
259 responses merit further research. TNF is a pleiotropic cytokine and its activities include maturation
260 of antigen presenting cells, modulation of T cell responses and stimulation of immunoglobulin
261 synthesis²⁵⁻²⁷. TNF neutralization, or genetic ablation, results in substantial loss of B-cells in primary
262 follicles in germinal centres, reduced numbers of memory B-cells in the periphery but preserved
263 numbers of T cells²⁵. Uncoupling of humoral and T cell immunity to SARS-CoV-2 has been observed
264 in healthy individuals²⁸, and although the relative contributions of memory B cell and T cell
265 responses have yet to be fully defined in SARS-CoV-2 immunity, the preservation of T cell immunity
266 reported here should provide some reassurance for anti-TNF treated patients. However, it is
267 noteworthy that one fifth made no anti-spike T cell response following two doses of either vaccine.
268 Chronic TNF exposure, a feature of many IMIDs, can render T cells anergic and can be reversed by
269 anti-TNF treatment²⁹. This may in part explain why the magnitude of T cell responses observed in

270 anti-TNF-treated patients in this study did not differ significantly from patients treated with
271 vedolizumab.

272 **Limitations**

273 Although our data show major differences in the magnitude and durability of antibody responses,
274 we have not assessed the impact of biologic therapy on specific immunoglobulin classes, antibody
275 neutralisation or mucosal immune responses, which may be impaired, in particular, with anti-a4b7
276 therapy^{30,31}. However, previous studies have demonstrated that anti-RBD antibody levels such as the
277 ones measured in this study, strongly correlate with Wuhan Hu-1 live virus neutralization assays³²
278 and we have demonstrated here that early antibody responses to vaccination correlates with the
279 subsequent risk of breakthrough infection in immunosuppressed patients.

280

281 **Conclusions**

282 Infliximab was associated with attenuated, less durable vaccine induced anti-SARS-CoV-2 spike
283 antibody responses and a 50% increase in subsequent breakthrough SARS-CoV-2 infection. Patients
284 treated with anti-TNF therapy should be prioritised for third vaccine doses.

285

286 **Methods**

287 **Patient and settings**

288 impaCt of bioLogic therApy on saRs-cov-2 Infection and immuniTY (CLARITY) IBD is a UK wide,
289 multicentre, prospective observational cohort study investigating the impact of infliximab and
290 vedolizumab and/or concomitant immunomodulators (azathioprine, mercaptopurine, and
291 methotrexate) on SARS-CoV-2 acquisition, illness, and immunity in patients with IBD.

292 Study methods have been previously described^{10,11}. Consecutive patients were recruited at the time
293 of attendance at infusion units between 22nd September 2020 and 23rd December 2020
294 (Supplementary Table 1). Patients aged 5 years and over, with a diagnosis of IBD, treated

295 with infliximab or vedolizumab were eligible for inclusion. Follow-up visits coincided with biologic
296 infusions and occurred eight-weekly. Here, we report vaccine-induced antibody responses after a
297 second-dose of either the BNT162b2 or ChAdOx1 nCoV-19 vaccines. Participants were eligible
298 for our primary immunogenicity analysis, if they had had an anti-S RBD antibody test between 14
299 and 70 days after a second-dose vaccine, defined as a second dose of any of the licenced COVID-
300 19 vaccines, 10-14 weeks after the first dose. Anti-S RBD antibody levels were compared with
301 samples from 605 fully vaccinated adult participants from the Virus Watch study, a household
302 community cohort of 10,000 individuals representative of the UK population of England and Wales
303 recruited between 1 June 2020 to 31 August 2021¹⁹. Peripheral blood mononuclear cells (PBMC) for
304 T cell experiments were collected from patients 4 to 6 weeks after the first and second dose of
305 vaccine at the time of biologic infusions, at selected sites which could facilitate PBMC extraction
306 within 12 hours of venepuncture.

307 ***Outcome measures***

308 Our primary outcome was anti-S RBD antibodies 2 to 10 weeks after second dose of the BNT162b2
309 or ChAdOx1 nCoV-19 vaccines.

310 Secondary outcomes were:

- 311 (i) the proportion of participants who seroconverted
- 312 (ii) anti-spike T cell responses in patients following the first and second dose of vaccines
- 313 (iii) the durability of vaccine responses
- 314 (iv) risk of breakthrough infections two or more weeks after two doses of vaccine
- 315 (v) antibody concentrations and seroconversion rates in patients with PCR or serological
316 evidence of past SARS-CoV-2 infection at, or prior, to the post-vaccination serum sample

317

318 ***Variables***

319 Variables recorded by participants were demographics (age, sex, ethnicity, comorbidities, height and
320 weight, smoking status, and postcode), IBD disease activity (PRO2), SARS-CoV-2 symptoms aligned to
321 the COVID-19 symptoms study (symptoms, previous testing, and hospital admissions for COVID-19),
322 and vaccine uptake (type and date of primary vaccination). Study sites completed data relating to
323 IBD history (age at diagnosis, disease duration, and phenotype according to the Montreal
324 classifications, previous surgeries, and duration of current biologic and immunomodulator
325 therapy)¹⁰. We linked our data by NHS number or Community Health Index to Public Health England,
326 Scotland, and Wales who archive dates and results of all SARS-CoV-2 PCR tests undertaken and
327 vaccines administered. Data were entered electronically into a purpose-designed REDCap database
328 hosted at the Royal Devon and Exeter NHS Foundation Trust³³. Participants without access to the
329 internet or electronic device completed their questionnaires on paper case record forms that were
330 subsequently entered by local research teams.

331

332 ***Laboratory methods***

333 To determine antibody responses specific to vaccination we used the Roche Elecsys Anti-SARS-CoV-2
334 spike (S) immunoassay³⁴ alongside the nucleocapsid (N) immunoassay³⁵. This double sandwich
335 electrochemiluminescence immunoassay uses a recombinant protein of the receptor binding
336 domain on the spike protein as an antigen for the determination of antibodies against SARS-CoV-2.
337 Sample electrochemiluminescence signals are compared to an internal calibration curve and
338 quantitative values are reported as units (U)/mL. In-house assay validation experiments were
339 previously reported and included in the Supplementary methods^{10,11}. Seroconversion was defined at
340 a threshold of 15 U/mL. ElecSys Anti-SARS-CoV-2 spike (S) RBD concentrations of greater than or
341 equal to 15 U/ml are associated with neutralization of $\geq 20\%$ with a positive predictive value of 99.10
342 % (95% CI: 97.74-99.64)¹¹.

343 At entry to CLARITY IBD and at follow-up visits, all patients were tested for previous SARS-CoV-2
344 infection using the Roche Elecsys anti-SARS-CoV-2 (N) immunoassay. We have previously reported
345 that anti-N antibody responses following SARS-CoV-2 natural infection are impaired in patients
346 treated with infliximab or vedolizumab¹¹. As such, a threshold 0.12 times above the cut-off index
347 was set, using receiver operator characteristic curve and area under the curve analysis of anti-N
348 antibody results from participants two weeks following a PCR-confirmed infection to maximise
349 specificity, beyond which patients were deemed to have had prior SARS-CoV-2 infection
350 (Supplementary Figure 7). Patients with a PCR test confirming SARS-CoV-2 infection at any time prior
351 to vaccination were deemed to have evidence of past infection irrespective of any antibody test
352 result. Breakthrough infections were defined by a positive SARS-CoV-2 PCR test 2 or more weeks
353 after the second vaccine dose.

354 ***Peripheral blood mononuclear cell isolation***

355 Whole blood was collected in lithium heparin tubes and PBMCs were isolated by density-gradient
356 centrifugation using LymphoprepTM (Stem Cell Technologies) layered on to SepMateTM (Stem Cell
357 Technologies) tubes. PBMC isolation was performed within 12 hours of venepuncture. Purified
358 PBMCs were cryopreserved in 10% DMSO/50% FBS and stored in liquid nitrogen pending batch
359 analysis.

360 ***Spike-peptide specific T cell responses***

361 IFN γ T cell ELISpot assays were performed using pre-coated plates (Mabtech 3420-2APT) and using
362 the protocol described previously^{28,32}. Two-hundred thousand cells were seeded per well and cells
363 were stimulated with a peptide pool, containing 18 peptides derived from SARS-CoV-2 spike
364 protein³⁶ at a concentration of 10 μ g/ml/peptide; the peptide pool utilises a mapped epitope pool
365 (MEP) or 12-20mer peptides, mapped as eliciting high-prevalence CD4 responses covering diverse
366 HLA-II haplotypes^{28,32}. Use of this spike MEP in otherwise healthy SARS-CoV-2 seropositive

367 individuals elicits a T cell response in 83% of individuals at 16 – 18 weeks after natural SARS-CoV-2
368 infection and 91% of healthy individuals 2-3 weeks after two dose vaccination with seronegative
369 individuals showing a level of response indistinguishable from pre-pandemic controls^{28,32}. Plates were
370 cultured for 18-20 hours before development and data collected using an AID classic ELISpot plate
371 reader (Autoimmun Diagnostika GMBH). Results are expressed as difference in (delta) spot forming
372 cells (SFC) per 10⁶ PBMC between peptide stimulation and a media only control. A response below 2
373 standard deviations of the media only control wells was deemed to be a null response. Data was
374 excluded if response to the positive control anti-CD3 stimulation was <200 SFC per 10⁶ PBMCs.

375 **Sample size**

376 The sample size for CLARITY IBD was based on the number of participants required to demonstrate a
377 difference in the impact of infliximab and vedolizumab on seroprevalence and seroconversion
378 following SARS-CoV-2 infection, with an estimated background seroprevalence of 0.05. We
379 calculated that a sample of 6970 patients would provide 80% power to detect differences in the
380 seroprevalence of SARS-CoV-2 antibodies in infliximab- compared with vedolizumab-treated
381 patients, whilst controlling for immunomodulator status at the 0.05 significance level.

382 **Statistical analyses**

383 Analyses were undertaken using R 4.1.0 (R Foundation for Statistical Computing, Vienna, Austria). All
384 tests were two tailed and p-values reported without correction for multiple testing. P-values <0.05
385 were considered significant. We included patients with missing clinical data in analyses for which
386 they had data and have specified the denominator for each variable. Anti-S RBD antibody
387 concentrations are reported as geometric means and standard deviations. Other continuous data
388 are reported as median and interquartile range, and discrete data as numbers and percentages,
389 unless otherwise stated.

390 Univariable analyses, using Spearman's rank correlation coefficients, and t-tests of log-transformed
391 anti-S RBD antibody concentration were used to identify demographic, disease, vaccine, and

392 treatment-related factors associated with the concentration of anti-S RBD antibodies across the
393 cohort. Crude sensitivity analyses excluding patients treated without a concomitant
394 immunomodulator were undertaken to control for the effect of immunomodulator use on anti-S
395 RBD antibody concentrations. Propensity matching was used to account for the other significant
396 differences in baseline variables between infliximab- and vedolizumab-treated patients using the
397 MatchIt package³⁷. A priori, patients were matched exactly on diagnosis, immunomodulator use, and
398 then using optimal matching, on age, number of comorbidities, ethnicity, and presence of active
399 disease. Multivariable linear regression models were used to identify factors independently
400 associated with log anti-S RBD concentration. A priori, we included age, ethnicity, biological
401 medication and immunomodulator use. Results are presented after exponentiation, so that the
402 coefficients of the model correspond to the fold change (FC) associated with each binary covariate.
403 For age, a cut-off was chosen based on graphical inspection of the relationship between age and
404 anti-S RBD antibody concentrations.

405 Mann-Whitney U test was used to compare the magnitude of T cell response (SFC/10⁶ PBMCs)
406 stratified by treatment and vaccine received, and Spearman's rank correlation coefficient was
407 calculated to determine correlation between antibody and T cell responses.

408 Anti-S RBD antibody half-lives were estimated using an exponential model of decay. Linear mixed
409 models were fit using the lme4 and lmerTest package, with biologic treatment and vaccine type as
410 fixed effects and each subject as a random effect. Each of these effects were estimated
411 independently for gradient and intercept. 95% confidence intervals of fixed effects were calculated
412 using likelihood ratios. P values for comparison of half-lives were estimated from the full linear
413 mixed effects model that incorporated vaccine, biologic drug and prior SARS-CoV-2 infection status.

414 We visualized durability of antibody responses by calculating 15-day rolling geometric mean anti-S
415 RBD antibody concentrations. For this analysis we included participants who had an antibody test
416 carried out between 1 and 70 days after second vaccine dose. Cox proportional hazard regression

417 models were used to identify demographic, disease and treatment-related factors associated with
418 the time to fall in anti-S RBD antibody concentration below the seroconversion threshold.

419 Kaplan-Meier curves and cox proportional hazard regression model was used to identify treatment-
420 related factors associated with time to breakthrough infection. Linear regression model of log-
421 transformed geometric mean anti-S RBD antibody concentration was used to determine the risk of
422 breakthrough infections.

423 Where appropriate the same analyses were used to compare antibody responses in participants
424 with PCR evidence of SARS-CoV-2 infection at any time prior to vaccination.

425

426 ***Ethical consideration and role of funders***

427 CLARITY IBD is an investigator-led, UK National Institute for Health Research COVID-19 urgent public
428 health study, funded by the Royal Devon and Exeter NHS Foundation Trust, NIHR Imperial
429 Biomedical Research Centre, Hull University Teaching Hospital NHS Trust, and by unrestricted
430 educational grants from F. Hoffmann-La Roche AG (Switzerland), Biogen GmbH (Switzerland),
431 Celltrion Healthcare (South Korea), Takeda (UK), and Galapagos NV (Belgium). None of our funding
432 bodies had any role in study design, data collection or analysis, writing, or decision to submit for
433 publication. Patients were included after providing informed, written consent. The sponsor was the
434 Royal Devon and Exeter NHS Foundation Trust. The Surrey Borders Research Ethics committee
435 approved the study (REC reference: REC 20/HRA/3114) in September 2020. The protocol is available
436 online at <https://www.clarityibd.org>. The study was registered with the ISRCTN registry
437 (ISRCTN45176516).

438 **Data availability**

439 The study protocol including the statistical analysis plan is available at www.clarityibd.org. Individual
440 participant de-identified data that underlie the results reported in this article will be available

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

441 immediately after publication for a period of 5 years. The data will be made available to
442 investigators whose proposed use of the data has been approved by an independent review
443 committee. Analyses will be restricted to the aims in the approved proposal. Proposals should be
444 directed to tariq.ahmad1@nhs.net. To gain access data requestors will need to sign a data access
445 agreement.

446 **Code availability**

447 Code used for data analysis will be available upon request directed to nick.kennedy1@nhs.net.
448

449

450 **References**

- 451 1. Bernal, J. L. *et al.* Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on
452 covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test
453 negative case-control study. *BMJ* **373**, (2021).
- 454 2. Voysey, M. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against
455 SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa,
456 and the UK. *www.thelancet.com* **397**, 2021 (2021).
- 457 3. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl. J.*
458 *Med.* **383**, 2603–2615 (2020).
- 459 4. Predecki, M. *et al.* Comparison of humoral and cellular responses in kidney transplant
460 recipients receiving BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines. *medRxiv*
461 2021.07.09.21260192 (2021) doi:10.1101/2021.07.09.21260192.
- 462 5. Wong, S.-Y. *et al.* Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines
463 in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. *Gastroenterology*
464 (2021) doi:10.1053/j.gastro.2021.04.025.
- 465 6. Kappelman, M. D. *et al.* Humoral Immune Response to mRNA COVID19 Vaccines among
466 Patients with IBD. *Gastroenterology* **0**, (2021).
- 467 7. Kearns, P. *et al.* Examining the Immunological Effects of COVID-19 Vaccination in Patients
468 with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE
469 Trial. *SSRN Electron. J.* (2021) doi:10.2139/SSRN.3910058.
- 470 8. Sakuraba, A., Luna, A. & Micic, D. Journal Pre-proof Serologic response to coronavirus disease
471 2019 (COVID-19) vaccination in patients with immune-mediated inflammatory diseases: a
472 systematic review and meta-analysis. (2021) doi:10.1053/j.gastro.2021.09.055.
- 473 9. Chanchlani, N. *et al.* Adalimumab and infliximab impair SARS-CoV-2 antibody responses:
474 results from a therapeutic drug monitoring study in 11422 biologic-treated patients. *J.*
475 *Crohn's Colitis* (2021) doi:10.1093/ECCO-JCC/JJAB153.
- 476 10. Kennedy, N. A. *et al.* Inflammatory bowel disease Anti-SARS-CoV-2 antibody responses are
477 attenuated in patients with IBD treated with infliximab. *Gut* **0**, 1–11 (2021).
- 478 11. Kennedy, N. A. *et al.* Infliximab is associated with attenuated immunogenicity to BNT162b2

- 479 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. *Gut* **0**, gutjnl-2021-324789
480 (2021).
- 481 12. Harrington, J. E., Hamilton, R. E., Ganley-Leal, L., Farraye, F. A. & Wasan, S. K. The
482 Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With
483 Inflammatory Bowel Disease Treated With Vedolizumab. *Crohn's Colitis* **360** **2**, (2020).
- 484 13. Joint Committee on Vaccination and Immunisation. Joint Committee on Vaccination and
485 Immunisation (JCVI) advice on third primary dose vaccination.
486 [https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-](https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination)
487 [people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-](https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination)
488 [immunisation-jcvi-advice-on-third-primary-dose-vaccination](https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination) (2021).
- 489 14. Centre for Disease Control and Prevention. COVID-19 Vaccines for Moderately to Severely
490 Immunocompromised People. [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html)
491 [ncov/vaccines/recommendations/immuno.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html) (2021).
- 492 15. European Medicines Agency. ECDC and EMA highlight considerations for additional and
493 booster doses of COVID-19 vaccines. [https://www.ema.europa.eu/en/news/ecdc-ema-](https://www.ema.europa.eu/en/news/ecdc-ema-highlight-considerations-additional-booster-doses-covid-19-vaccines)
494 [highlight-considerations-additional-booster-doses-covid-19-vaccines](https://www.ema.europa.eu/en/news/ecdc-ema-highlight-considerations-additional-booster-doses-covid-19-vaccines) (2021).
- 495 16. National Advisory Committee on Immunization (NACI). Summary of National Advisory
496 Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in
497 immunocompromised individuals following a 1- or 2-dose primary series.
498 [https://www.canada.ca/en/public-health/services/immunization/national-advisory-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html?utm_campaign=hc-sc-covidvaccine-21-22)
499 [committee-on-immunization-naci/summary-september-10-2021-additional-dose-covid-19-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html?utm_campaign=hc-sc-covidvaccine-21-22)
500 [vaccine-immunocompromised-following-1-2-dose-series.html?utm_campaign=hc-sc-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html?utm_campaign=hc-sc-covidvaccine-21-22)
501 [covidvaccine-21-22](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html?utm_campaign=hc-sc-covidvaccine-21-22) (2021).
- 502 17. Hall, V. G. *et al.* Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant
503 Recipients. <https://doi.org/10.1056/NEJMc2111462> (2021) doi:10.1056/NEJMC2111462.
- 504 18. EE, W. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *N.*
505 *Engl. J. Med.* **383**, 2439–2450 (2020).
- 506 19. Shrotri, M. *et al.* Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. *Lancet*
507 **0**, (2021).
- 508 20. McDonald, I., Murray, S. M., Reynolds, C. J., Altmann, D. M. & Boyton, R. J. Comparative

- 509 systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of
510 vaccines against SARS-CoV-2. *npj Vaccines* 2021 61 6, 1–14 (2021).
- 511 21. Thomas, S. J. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6
512 Months. <https://doi.org/10.1056/NEJMoa2110345> (2021) doi:10.1056/NEJMoa2110345.
- 513 22. Park, J. K. *et al.* Effect of methotrexate discontinuation on efficacy of seasonal influenza
514 vaccination in patients with rheumatoid arthritis: A randomised clinical trial. *Ann. Rheum. Dis.*
515 **76**, 1559–1565 (2017).
- 516 23. Barros-Martins, J. *et al.* Immune responses against SARS-CoV-2 variants after heterologous
517 and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. *Nat. Med.* 2021 1–5 (2021)
518 doi:10.1038/s41591-021-01449-9.
- 519 24. Lazarus, R. *et al.* The Safety and Immunogenicity of Concomitant Administration of COVID-19
520 Vaccines (ChAdOx1 or BNT162b2) with Seasonal Influenza Vaccines in Adults: A Phase IV,
521 Multicentre Randomised Controlled Trial with Blinding (ComFluCOV). *SSRN Electron. J.* (2021).
- 522 25. Pasparakis, M., Alexopoulou, L., Episkopou, V. & Kollias, G. Immune and inflammatory
523 responses in TNF α -deficient mice: A critical requirement for TNF α in the formation of primary
524 B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation
525 of the humoral immune response. *J. Exp. Med.* **184**, 1397–1411 (1996).
- 526 26. Ritter, U., Meissner, A., Ott, J. & Körner, H. Analysis of the maturation process of dendritic
527 cells deficient for TNF and lymphotoxin- α reveals an essential role for TNF. *J. Leukoc. Biol.* **74**,
528 216–222 (2003).
- 529 27. Salinas, G. F. *et al.* Anti-TNF treatment blocks the induction of T cell-dependent humoral
530 responses. *Ann. Rheum. Dis.* **72**, 1037–1043 (2013).
- 531 28. Reynolds, C. J. *et al.* Discordant neutralizing antibody and T cell responses in asymptomatic
532 and mild SARS-CoV-2 infection. *Sci. Immunol.* **5**, (2020).
- 533 29. Cope, A. P. *et al.* Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the
534 activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF
535 antibodies in patients with rheumatoid arthritis. *J. Clin. Invest.* **94**, 749–760 (1994).
- 536 30. Sandborn, W. J. *et al.* Vedolizumab as Induction and Maintenance Therapy for Crohn's
537 Disease. *N. Engl. J. Med.* **369**, 711–721 (2013).

- 538 31. Bourges, D. *et al.* Differential expression of adhesion molecules and chemokines between
539 nasal and small intestinal mucosae: implications for T- and IgA+ B-lymphocyte recruitment.
540 *Immunology* **122**, 551–561 (2007).
- 541 32. Reynolds, C. J. *et al.* Prior SARS-CoV-2 infection rescues B and T cell responses to variants
542 after first vaccine dose. *Science* **372**, 1418–1423 (2021).
- 543 33. Harris, P. A. *et al.* The REDCap consortium: Building an international community of software
544 platform partners. *Journal of Biomedical Informatics* vol. 95 (2019).
- 545 34. Roche Diagnostics GmbH. Elecsys® Anti-SARS-CoV-2 S assay method sheet.
546 <https://diagnostics.roche.com/gb/en/products/params/electsys-anti-sars-cov-2-s.html> (2020).
- 547 35. Muench, P. *et al.* Development and validation of the elecsys anti-SARS-CoV-2 immunoassay
548 as a highly specific tool for determining past exposure to SARS-CoV-2. *J. Clin. Microbiol.* **58**,
549 1694–1714 (2020).
- 550 36. Peng, Y. *et al.* Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK
551 convalescent individuals following COVID-19. *Nat. Immunol.* **21**, 1336 (2020).
- 552 37. Ho, D. E., Imai, K., King, G. & Stuart, E. A. MatchIt: Nonparametric preprocessing for
553 parametric causal inference. *J. Stat. Softw.* **42**, 1–28 (2011).
554

555 **Acknowledgements**

556 CLARITY IBD is a UK National Institute for Health Research (NIHR) Urgent Public Health Study. The
557 NIHR Clinical Research Network supported study set-up, site identification, and delivery of this
558 study. This was facilitated by Professor Mark Hull, the National Speciality Lead for Gastroenterology.
559 We acknowledge the contribution of our Patient Advisory Group who helped shape the trial design
560 around patient priorities. Our partners, Crohn's and Colitis UK (CCUK), continue to support this
561 group and participate in Study Management Team meetings. We thank Professor Graham Cooke and
562 Dr Katrina Pollock for their helpful discussions and review of the data. Laboratory tests were
563 undertaken by the Exeter Blood Sciences Laboratory at the Royal Devon and Exeter NHS Foundation
564 Trust. The Exeter NIHR Clinical Research Facility coordinated sample storage and management. Tariq
565 Malik and James Thomas from Public Health England, Guy Stevens, Katie Donelon, Elen de Lacy from
566 Public Health Wales and Johanna Bruce from Public Health Scotland supported linkage of central
567 SARS-CoV-2 PCR test results with study data. Roche Diagnostics Limited provided the Elecsys Anti-
568 SARS-CoV-2 immunoassay for the study. Faculty of Medicine at Imperial College London, Exeter NIHR
569 Clinical Research Facility, Jeffrey Cheah Biomedical Centre at the University of Cambridge, Newcastle
570 University Medical School and The Queen's Medical Research Institute at the University of
571 Edinburgh facilitated PBMC extractions for the T cell experiments. We thank Professor Robert
572 Aldridge for access to data from the Virus Watch Collaborative. SL is supported by a Wellcome GW4-
573 CAT fellowship. NC acknowledges support from CCUK. JCL is a Lister Prize Fellow and acknowledges
574 support from the Cambridge NIHR Biomedical Research Centre and the Francis Crick Institute which
575 receives core funding from Cancer Research UK (FC001169), the UK Medical Research Council
576 (FC001169), and the Wellcome Trust (FC001169). GRJ is supported by a Wellcome Trust Clinical
577 Research Career Development Fellowship (220725/Z/20/Z). CAL acknowledges support from the
578 NIHR Newcastle Biomedical Research Centre and the support of the Programmed Investigation Unit
579 at Royal Victoria Infirmary, Newcastle upon Tyne. CWL is funded by a UKRI Future Leaders
580 Fellowship. RJB and DMA are supported by MRC (MR/W020610/1, MR/S019553/1, MR/R02622X/1

581 and MR/V036939/1), NCSi4P, NIHR EME NIHR134607 and NIHR COV-LT2-0027, Innovate UK
582 SBRI894, NIHR Imperial Biomedical Research Centre (BRC):ITMAT, Cystic Fibrosis Trust SRC
583 (2019SRC015), and Horizon 2020 Marie Skłodowska-Curie Innovative Training Network (ITN)
584 European Training Network (No 860325). NP is supported by the NIHR Imperial Biomedical Research
585 Center (BRC). We acknowledge the study co-ordinators of the Exeter Inflammatory Bowel Disease
586 Research Group: Marian Parkinson and Helen Gardner-Thorpe for their ongoing administrative
587 support to the study. The sponsor of the study was the Royal Devon and Exeter NHS Foundation
588 Trust.

589 **Author Contributions**

590 NAK, JRG, CB, SS, NP, TA participated in the conception and design of this study. CB was the project
591 manager and coordinated patient recruitment. RN and TJM coordinated all biochemical analyses and
592 central laboratory aspects of the project. SL, NAK, AS, DMS, CJR, RCS, SHK, FPP, KML, DKB, NC,
593 DC, CB, MJ, SS, JLA, LC, JCL, CDM, ALH, PMI, GRJ, KBK, CAL, CWL, DMA, RJB, JRG, NP, TA were
594 involved in the acquisition, analysis, or interpretation of data. DMS, CJR, KML, DKB, and FPP
595 performed, analysed and interpreted T cell experiments. T cell experiments
596 were supervised, designed, analysed and interpreted by RJB and DMA. Data analysis was done by
597 NAK, DMS and RJB. Drafting of the manuscript was done by SL, NAK, NC, SS, CWL, DMA, RJB, JRG,
598 NP, TA. NP and TA obtained the funding for the study. All the authors contributed to the critical
599 review and final approval of the manuscript. NAK, NP and TA have verified the underlying data.

600

601 **Competing interests**

602 Dr. S Lin reports non-financial support from Pfizer, non-financial support from Ferring, outside the
603 submitted work. Dr. Kennedy reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc,
604 grants from Celltrion Healthcare, grants from Galapagos NV, non-financial support
605 from Immundiagnostik, during the conduct of the study; grants and non-financial support from
606 AbbVie, grants and personal fees from Celltrion, personal fees and non-financial support from
607 Janssen, personal fees from Takeda, personal fees and non-financial support from Dr Falk, outside
608 the submitted work. Dr Saifuddin has received travel expense support from Dr Falk Pharma. Dr. Chee
609 reports non-financial support from Ferring, personal fees and non-financial support from Pfizer,
610 outside the submitted work. Prof. Sebastian reports grants from Takeda, Abbvie,
611 AMGEN, Tillots Pharma, personal fees from Jaansen, Takeda, Galapagos, Celltrion, Falk
612 Pharma, Tillots pharma, Cellgene, Pfizer, Pharmacocosmos, outside the submitted work. Dr
613 Alexander reports sponsorship from Vifor Pharma for accommodation/travel to BSG 2019, outside
614 the submitted work. Dr Lee reports personal fees from Abbvie, personal fees from C4X Discovery,
615 personal fees from PredictImmune and personal fees from AG pus diagnostics.
616 Dr Hart reports personal fees from Abbvie, personal fees from Allergan, personal fees from BMS,
617 personal fees from Celltrion, personal fees from Falk, personal fees from GSK, personal fees from
618 Takeda, personal fees from Pfizer, personal fees from Janssen, personal fees from Galapagos,
619 personal fees from Astra Zeneca, outside the submitted work. Dr Irving reports grants and personal
620 fees from Takeda, grants from MSD, grants and personal fees from Pfizer, personal fees from
621 Galapagos, personal fees from Gilead, personal fees from Abbvie, personal fees from Janssen,
622 personal fees from Boehringer Ingelheim, personal fees from Topivert, personal fees from VH2,
623 personal fees from Celgene, personal fees from Arena, personal fees from Samsung Bioepis,
624 personal fees from Sandoz, personal fees from Procise, personal fees from Prometheus, outside the
625 submitted work. Dr Jones has received speaker fees from Takeda, Ferring and Janssen. Dr. Kok
626 reports personal fees from Janssen, personal fees from Takeda, personal fees from PredictImmune,

627 personal fees from Amgen, outside the submitted work. Dr. Lamb reports grants from Genentech,
628 grants and personal fees from Janssen, grants and personal fees from Takeda, grants from AbbVie,
629 personal fees from Ferring, grants from Eli Lilly, grants from Pfizer, grants from Roche, grants from
630 UCB Biopharma, grants from Sanofi Aventis, grants from Biogen IDEC, grants from Orion OYJ,
631 personal fees from Dr Falk Pharma, grants from AstraZeneca, outside the submitted work. Prof. Lees
632 reports personal fees from Abbvie, personal fees from Janssen, personal fees from Pfizer, personal
633 fees from Takeda, grants from Gilead, personal fees from Gilead, personal fees from Galapagos,
634 personal fees from Iterative Scopes, personal fees from Trellus Health, personal fees from Celltion,
635 personal fees from Ferring, personal fees from BMS, during the conduct of the study. Prof Boyton
636 and Prof Altmann are members of the Global T cell Expert Consortium and have consulted for
637 Oxford Immunotec outside the submitted work. Dr. Goodhand reports grants from F. Hoffmann-La
638 Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV, non-
639 financial support from Immundiagnostik, during the conduct of the study. Dr. Powell reports
640 personal fees from Takeda, personal fees from Janssen, personal fees from Pfizer, personal fees
641 from Bristol-Myers Squibb, personal fees from Abbvie, personal fees from Roche, personal fees from
642 Lilly, personal fees from Allergan, personal fees from Celgene, outside the submitted work;
643 and Dr. Powell has served as a speaker/advisory board member for Abbvie, Allergan, Bristol Myers
644 Squibb, Celgene, Falk, Ferring, Janssen, Pfizer, Tillotts, Takeda and Vifor Pharma. Prof. Ahmad
645 reports grants and non-financial support from F. Hoffmann-La Roche AG, grants from Biogen Inc,
646 grants from Celltrion Healthcare, grants from Galapagos NV, non-financial support
647 from Immundiagnostik, during the conduct of the study; personal fees from Biogen inc, grants and
648 personal fees from Celltrion Healthcare, personal fees and non-financial support
649 from Immundiagnostik, personal fees from Takeda, personal fees from ARENA, personal fees from
650 Gilead, personal fees from Adcock Ingram Healthcare, personal fees from Pfizer, personal fees from
651 Genentech, non-financial support from Tillotts, outside the submitted work. The following authors
652 have nothing to declare: Diana Muñoz Sandoval, Catherine Reynolds, Rocio Castro Seoane, Sherine H

653 Kottoor, Franziska Pieper, Kai-Min Lin, David Butler, Neil Chanchlani, Claire Bewshea, Rachel Nice,

654 Laura Constable, Charles D Murray, Timothy J McDonald.

655

656 **Table**


Variable	Level	Vedolizumab	Infliximab	Overall	p
Vaccine	BNT162b2	40.0% (410/1024)	40.1% (907/2264)	40.1% (1317/3288)	1.0
	ChAdOx1 nCoV-19	60.0% (614/1024)	59.9% (1357/2264)	59.9% (1971/3288)	
Age (years)		48.0 (35.1 - 61.5)	40.2 (30.0 - 53.1)	42.0 (31.3 - 55.7)	<0.0001
Sex	Female	48.0% (490/1021)	45.9% (1038/2260)	46.6% (1528/3281)	0.16
	Male	51.8% (529/1021)	54.0% (1221/2260)	53.3% (1750/3281)	
	Intersex	0.0% (0/1021)	0.0% (0/2260)	0.0% (0/3281)	
	Prefer not to say	0.2% (2/1021)	0.0% (1/2260)	0.1% (3/3281)	
Ethnicity	White	89.9% (917/1020)	92.6% (2091/2259)	91.7% (3008/3279)	0.029
	Asian	6.5% (66/1020)	4.6% (103/2259)	5.2% (169/3279)	
	Mixed	2.5% (25/1020)	1.4% (32/2259)	1.7% (57/3279)	
	Black	0.5% (5/1020)	0.8% (18/2259)	0.7% (23/3279)	
	Other	0.7% (7/1020)	0.7% (15/2259)	0.7% (22/3279)	
Diagnosis	Crohn's disease	36.9% (378/1024)	67.2% (1521/2264)	57.8% (1899/3288)	<0.0001
	UC/IBDU	63.1% (646/1024)	32.8% (743/2264)	42.2% (1389/3288)	
Duration of IBD (years)		9.0 (5.0 - 17.0)	8.0 (3.0 - 16.0)	8.5 (4.0 - 16.0)	0.00015
Age at IBD diagnosis (years)		33.5 (22.8 - 47.2)	27.6 (20.2 - 39.5)	29.2 (20.8 - 42.1)	<0.0001
Immunomodulators at vaccine		20.5% (207/1009)	57.7% (1295/2244)	46.2% (1502/3253)	<0.0001
5-ASA		33.8% (341/1009)	20.6% (463/2244)	24.7% (804/3253)	<0.0001
Steroids		5.9% (60/1009)	2.8% (62/2244)	3.8% (122/3253)	<0.0001
BMI		25.9 (23.0 - 29.8)	25.9 (22.8 - 30.1)	25.9 (22.9 - 30.0)	0.81
Heart disease		4.8% (49/1020)	2.6% (59/2256)	3.3% (108/3276)	0.0020
Diabetes		7.6% (78/1020)	3.6% (82/2256)	4.9% (160/3276)	<0.0001
Lung disease		16.5% (168/1020)	13.1% (295/2256)	14.1% (463/3276)	0.011
Kidney disease		1.8% (18/1020)	0.8% (17/2256)	1.1% (35/3276)	0.015
Cancer		1.6% (16/1020)	0.3% (6/2256)	0.7% (22/3276)	<0.0001
Smoker	Yes	8.1% (83/1020)	10.8% (244/2256)	10.0% (327/3276)	0.00050
	Not currently	37.6% (384/1020)	30.2% (682/2256)	32.5% (1066/3276)	
	Never	54.2% (553/1020)	59.0% (1330/2256)	57.5% (1883/3276)	
Exposure to documented cases of COVID-19		7.8% (80/1020)	8.6% (194/2256)	8.4% (274/3276)	0.50
Income deprivation score		0.089 (0.055 - 0.146)	0.091 (0.052 - 0.153)	0.090 (0.053 - 0.151)	0.86
Active disease (PRO2)		10.5% (100/956)	5.1% (109/2132)	6.8% (209/3088)	<0.0001
Time between vaccine doses (weeks)		10.9 (9.7 - 11.1)	11.0 (10.0 - 11.3)	10.9 (10.0 - 11.3)	0.0042
Time from second dose to serum sample (weeks)		5.7 (3.7 - 7.7)	5.7 (3.7 - 7.7)	5.7 (3.7 - 7.7)	0.74

657

658 **Table 1: Baseline characteristics of participants who had anti-S RBD antibodies measured 2 to 10**

659 **weeks following 2 doses of COVID-19 vaccine**


660 Abbreviations: IBD = inflammatory bowel disease; 5-ASA = 5-aminosalicylic acid; BMI = Body Mass
661 Index; PRO2 = IBD disease activity. Values presented are median (interquartile range) or percentage
662 (numerator/denominator). P values represent the results of a Mann Whitney U, Kruskal Wallis or
663 Fisher's exact test.



664

665 **Figure 1: Anti-S RBD antibody concentration stratified by biologic therapy (infliximab**
666 **vs vedolizumab), type of vaccine, vaccine dose and history of prior SARS-CoV-2 infection. The**
667 **wider bar represents the geometric mean, while the narrower bars are drawn one geometric**
668 **standard deviation either side of the geometric mean. Based on published data using neutralization**
669 **assays threshold shown of 15 U/mL was used to determine seroconversion¹¹. The biologic treatment**
670 **infliximab is shown in green and vedolizumab in orange. The number of individuals tested for each**
671 **group are shown in black at the top of each panel.**

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



672

673 **Figure 2: Exponentiated coefficients of linear regression models of log anti-S RBD antibody**

674 **concentration**

675 Exponentiated coefficients of linear regression model of log anti-S RBD antibody concentration in

676 participants who received **a.** BNT162b2 vaccine. **b.** ChAdOx1 nCoV-19 vaccine. **c.** either the


677 BNT162b2 or ChAdOx1 nCoV-19 vaccine. The resultant values represent the fold change of antibody

678 concentration associated with each variable. Each vaccine was modelled separately, and then a

679 further model was created using all available data. Horizontal dotted line represents a fold change of

680 1. Abbreviations: UC = ulcerative colitis, IBDU = IBD unclassified

681




682

683 **Figure 3. Anti-SARS-CoV-2 spike T cell responses stratified by vaccine platform (BNT162b2 vs**
684 **ChAdOx1 nCoV-19), biologic therapy (infliximab vs vedolizumab), and vaccine dose (one vs two).**

685 **a.** Spike MEP T cell responses SFC per 10^6 PBMC stratified by vaccine platform, biologic therapy
686 (infliximab vs vedolizumab) and number of vaccine doses. The horizontal bar represents the
687 geometric mean and the narrow bars represent one geometric standard deviation either side of the
688 geometric mean. The number of T cell responders / total number of individuals tested are shown in
689 black at the top of each panel. **b.** Scatterplot demonstrating the correlation between T cell responses
690 against spike MEP pool (SFC per 10^6 PBMC) and anti-SARS-CoV-2 spike antibody concentration after
691 the first (LHS) and second (RHS) dose of BNT162B2 (top) and ChAdOx1 nCoV-19 (bottom) vaccine.
692 The number of non-T cell responders / total number of individuals tested is shown in blue on the
693 bottom RHS of each panel. The horizontal dotted line in **b.** represents a threshold of 15 U/mL of anti-
694 S1 SARS-CoV-2 antibody. The biologic infliximab is shown in green and vedolizumab is shown in
695 orange. R, Spearman's rank correlation. SFC, spot forming cells. PBMC, peripheral blood
696 mononuclear cell. MEP, mapped epitope peptide.

697




698

699 **Figure 4: Anti-spike T cell responses ordered by cumulative magnitude of anti-S RBD following two**
700 **doses of the BNT162b2 or ChAdOx1 nCoV-19 vaccine shows uncoupling of the T cell and antibody**
701 **responses**

702 Top panel shows T cell responses to spike, and bottom panel shows anti-S RBD responses plotted for
703 individual study participants ordered by increasing magnitude of anti-S RBD antibody concentration
704 (U/mL). The vertical dark grey bars at the LHS of the panels indicate individuals with no anti-S RBD
705 response. The vertical light grey bars in the panels indicate individuals with no T cell response. The
706 horizontal dotted line represents a threshold shown of 15 U/mL of anti-S RBD.


707



708

709 **Figure 5: Rolling geometric mean antibody concentration over time from the date of the second**
710 **dose of the SARS-CoV-2 vaccine (week 0) stratified by biologic therapy (infliximab vs vedolizumab),**
711 **vaccine, and history of prior SARS-CoV-2 infection.** Geometric means are calculated using a
712 rolling 15-day window (i.e. 7 days either side of the day indicated). The shaded areas represent the
713 95% confidence intervals of the geometric means. The horizontal blue line represents the
714 seroconversion threshold (15 U/mL). The number of participants included at each time point is
715 presented in Supplementary Figure 3. Overall, data from 4429 participants with no history of prior
716 infection (2999 on infliximab and 1430 on vedolizumab) and 1170 participants with a history of prior
717 infection (825 on infliximab and 345 on vedolizumab) were included in this graph between 22 weeks
718 before and 29 weeks after the second vaccine dose. The biologic treatment infliximab is shown in
719 green and vedolizumab is shown in orange.

720



721

722 **Figure 6: Kaplan-Meier graphs comparing the time to PCR-confirmed SARS-CoV-2 infection**
 723 **stratified by biologic therapy (infliximab vs vedolizumab) in participants before vaccination and**
 724 **after receiving two doses of vaccine.**

725 **a)** The time to PCR-confirmed SARS-CoV-2 infection in participants who have not received any dose
 726 of either vaccine stratified by biologic therapy (infliximab vs vedolizumab). **b)** The time to a PCR-
 727 confirmed SARS-CoV-2 breakthrough infection in participants following two doses of either vaccine
 728 stratified by biologic therapy. The biologic treatment infliximab is shown in green and vedolizumab
 729 in orange. The number of participants at each time point are displayed in black at the bottom of
 730 each figure. P-values are calculated using log-rank test.